CoChat

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

· 2017 · New England Journal of Medicine
Cited by 144

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

To the Editor: In reporting the results of the Trial to Evaluate Cardiovascular and Other Longterm Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6), Marso et al. (Nov.10 issue) 1 describe a lower rate of cardiovascular events among patients with type 2 diabetes mellitus who received the glucagon-like peptide 1 (GLP-1) analogue semaglutide than among patients who received placebo.Their results are consistent with those in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, 2 which assessed the effects of another GLP-1 analogue, liraglutide.In SUSTAIN-6, the use of insulin at trial entry was similar between the two groups.However, during the LEADER trial, the use of insulin was approximately two times higher in the placebo group than in the liraglutide group, and during SUSTAIN-6, the use of insulin was approximately three times higher in the placebo group than in the semaglutide group.The significantly greater use of insulin in the placebo groups in these two trials may, at least in part, explain the increase in the risk of death from any cause as well as the increase in the risks of heart failure, cardiovascular events, renal failure, and hypoglycemia in these two groups.Hazard ratios for these events associated with increased use of insulin range from 1.23 to 4.57, as shown in two cohort studies in primary care. 3,4Thus, we wonder whether the greater use of insulin in the placebo groups than in the liraglutide and semaglutide groups during these trials may have amplified the beneficial effects of liraglutide and semaglutide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmc1615712

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 6

  1. 10.1136/bmj.i3477 · DOI · Paper page
  2. 10.1136/bmj.i1450 · DOI
  3. 10.1016/j.diabres.2013.03.018 · DOI · Paper page
  4. 10.2337/diacare.18.12.1571 · DOI
  5. 10.2337/diacare.28.12.2819 · DOI
  6. 10.1056/NEJMoa1603827 · DOI · Paper page

Cited by

See all 144

Metadata

Venue
New England Journal of Medicine
Published
2017-03-02
Volume
376
Issue
9
Pages
890-892
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3049003652
Cited by
144
References
4
FWCI
6.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.